Clinical and pathological indexes | Training cohort | Validation cohort | P | Combined cohort |
---|---|---|---|---|
N = 138 (%) | N = 171 (%) | N = 309 (%) | ||
Age (y) | ||||
 ≤ 60 | 47 (34.06) | 65 (38.01) | 0.472 | 112 (36.25) |
 > 60 | 91 (65.94) | 106 (61.99) |  | 197 (63.75) |
Gender | ||||
 Male | 81 (58.70) | 90 (52.63) | 0.286 | 171 (55.34) |
 Female | 57 (41.30) | 81 (47.37) |  | 138 (44.66) |
Smoking | ||||
 No | 89 (64.49) | 133 (77.78) | 0.010 | 222 (71.84) |
 Yes | 49 (35.51) | 38 (22.22) |  | 87 (28.16) |
Alcohol use | ||||
 No | 104 (75.36) | 141 (82.46) | 0.126 | 245 (79.29) |
 Yes | 34 (24.64) | 30 (17.54) |  | 64 (20.71) |
Tumor size | ||||
 T1–T2 | 103 (74.64) | 135 (78.95) | 0.371 | 238 (77.02) |
 T3–T4 | 35 (25.36) | 36 (21.05) |  | 71 (22.98) |
Pathological grade | ||||
 I | 83 (60.14) | 95 (55.56) | 0.417 | 178 (57.61) |
 II–III | 55 (39.86) | 76 (44.44) |  | 131 (42.39) |
Cervical nodal metastasis | ||||
 N0 | 112 (81.16) | 121 (70.76) | 0.035 | 233 (75.40) |
 N+ | 26 (18.84) | 50 (29.24) |  | 76 (24.60) |
Clinical stage | ||||
 I–II | 91 (65.94) | 100 (58.48) | 0.180 | 191 (61.81) |
 III–IV | 47 (34.06) | 71 (41.52) |  | 118 (38.19) |
SII | ||||
 < 484.5 | 96 (69.57) | 105 (61.40) | 0.135 | 201 (65.05) |
 ≥ 484.5 | 42 (30.43) | 66 (38.60) |  | 108 (34.95) |
NLR | ||||
 < 2.9 | 109 (78.99) | 129 (75.44) | 0.461 | 238 (77.02) |
 ≥ 2.9 | 29 (21.01) | 42 (24.56) |  | 71 (22.98) |
PLR | ||||
 < 170.2 | 114 (82.61) | 129 (75.44) | 0.126 | 243 (78.64) |
 ≥ 170.2 | 24 (17.39) | 42 (24.56) |  | 66 (21.36) |
Median survival (months) | 48 (4–134) | 45 (4–138) |  | 46 (4–138) |